Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures: 2020-2024

Historic Gains from Sales and Divestitures for Revolution Medicines (RVMD) over the last 5 years, with Dec 2024 value amounting to $1.0 million.

  • Revolution Medicines' Gains from Sales and Divestitures rose 34.97% to $978,467 in Q3 2025 from the same period last year, while for Sep 2025 it was $978,467, marking a year-over-year increase of 34.97%. This contributed to the annual value of $1.0 million for FY2024, which is 75.27% up from last year.
  • Latest data reveals that Revolution Medicines reported Gains from Sales and Divestitures of $1.0 million as of FY2024, which was up 75.27% from $576,974 recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Gains from Sales and Divestitures peaked at $1.0 million during FY2024, and registered a low of $1,681 during FY2020.
  • For the 3-year period, Revolution Medicines' Gains from Sales and Divestitures averaged around $622,359, with its median value being $576,974 (2023).
  • Data for Revolution Medicines' Gains from Sales and Divestitures shows a peak YoY soared of 4,540.69% (in 2021) over the last 5 years.
  • Revolution Medicines' Gains from Sales and Divestitures (Yearly) stood at $1,681 in 2020, then surged by 4,540.69% to $78,010 in 2021, then skyrocketed by 257.45% to $278,848 in 2022, then spiked by 106.91% to $576,974 in 2023, then surged by 75.27% to $1.0 million in 2024.